Genetic analysis company OpGen (Gaithersburg, MD) has launched a clinical services laboratory that will focus on developing genetic tests and analysis services for the surveillance and identification of healthcare-associated infections (HAIs) and human pathogens. The new lab has received Clinical Laboratory Improvement Amendments (CLIA) certification.
Related: First-ever stoppage of MRSA outbreak by gene sequencing technology
Related: Optical-driven microbial sequence database collaboration in the works
Related: DNA sequencing technologies: The next generation and beyond
The company's clinical services laboratory utilizes next-generation DNA and genetic analysis technologies that include multiplex real-time polymerase chain reaction (PCR), whole genome mapping, and next-generation sequencing for screening, surveillance, diagnosis, gene content, and epidemiologic analysis of infectious diseases. It offers Whole Genome Mapping genetic analysis of HAIs, as well as sequence analysis of C. difficile on a worldwide basis. It will also offer real-time PCR screening and surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and complete C. difficile hyper-virulence diagnostic testing services in the mid-Atlantic region. And they are actively developing tests for a broad array of gram-negative and gram-positive multi-drug-resistant organisms.
"With the significant mortality and costs associated with HAIs along with growing prevalence and concerns surrounding multi-drug resistant organisms, clinicians, hospitals, and public health agencies need to be able to rapidly identify healthcare associated infections to effectively treat patients while minimizing the risk of outbreaks," says Douglas White, chief executive officer of OpGen. "OpGen is building on the success of our Whole Genome Mapping applications in the public health and life sciences sectors to expand our capabilities to help hospitals and healthcare facilities combat HAIs and complex human pathogens."
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!